课题基金 / 基金详情

Neurosteroids as a standard medical countermeasure for OP poisoning

Neurosteroids as a standard medical countermeasure for OP poisoning
神经类固醇作为 OP 中毒的标准医疗对策
批准号:
9352480
负责人:
KELVIN W. GEE
金额:
$43.46万
依托单位国家:
美国
项目类别:
财政年份:
2017
资助国家:
美国
项目状态:
已结题
起止时间:
2017-08-01 至 2020-04-30

项目摘要

项目成果

KELVIN W. GEE的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Acute organophosphorous poisoning is a military and civilian threat that causes a complex cascade of lethal central and peripheral nervous system toxicities. Identifying new and improved therapeutics to treat and/or prevent central nervous system (CNS) injuries resulting from exposure to chemical threats is a mission for the NIH Countermeasures Against Chemical Threats (CounterACT) program. This grant proposal seeks support for research on the identification of a small molecule lead candidate compound to block status epilepticus (SE) seizures caused by chemical warfare agent exposure. The objective of this proposal is to test the anticonvulsant efficacy of synthetic neuroactive steroids as an adjunct to standard medical countermeasures for soman-induced SE in a delayed treatment rodent model. Our studies will result in synthetically feasible compounds that are biologically active with specificity, affinity, potency, efficacy and target selectivity towards extrasynaptic α4β3δ subunit containing γ-aminobutyric acid-A receptors (GABAARs) for counteracting CNS toxicities arising from OP nerve agent exposure. We propose to demonstrate in vivo proof-of-concept efficacy data of one lead optimization compound ready for advanced therapeutic development plus a suitable backup molecule. The impact of the proposed research will be to understand if pharmacological targeting of extrasynaptic GABAARs is a strategy for designing effective medical countermeasures to chemical weapons exposure.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Pain drugs based on nicotinic receptor subtype antagonists
  • 批准号:
    9763538
  • 项目类别:
  • 资助金额:
    $73.96万
  • 财政年份:
    2017
  • 负责人:
    KELVIN W. GEE
  • 依托单位:
Pain drugs based on nicotinic receptor subtype antagonists
  • 批准号:
    9238320
  • 项目类别:
  • 资助金额:
    $79.04万
  • 财政年份:
    2017
  • 负责人:
    KELVIN W. GEE
  • 依托单位:
Drug Development
  • 批准号:
    8330550
  • 项目类别:
  • 资助金额:
    $36.91万
  • 财政年份:
    2011
  • 负责人:
    KELVIN W. GEE
  • 依托单位:
Development of Dual GABAA and alpah7 Nicotinic Receptor Modulators for AD
  • 批准号:
    8132764
  • 项目类别:
  • 资助金额:
    $10.51万
  • 财政年份:
    2010
  • 负责人:
    KELVIN W. GEE
  • 依托单位:
海外基金